Original news and analysis on international IP policy
The Executive Board session of the World Health Organization ended early on Monday after a week of discussions that settled some issues but left some others for the next governing meeting of the organisation in May, with much to do until then. The WHO is facing a significant gap in its budget and a programme of reforms is brewing.
World Health Organization members yesterday struck a compromise allowing a Swiss industry representative to sit on a committee selecting proposals for research and developing financing for neglected diseases, disregarding the fact that he is author of one of the proposals. Special safeguards were added to prevent undue influence, but questions remain for some about a conflict of interest.
World Health Organization members today raised strong concerns that a working group they mandated last May to address problems with WHO policy on counterfeit and substandard medicines has yet to be formed - with four months remaining before it must report back to members.
One delegation called for a halt to WHO activities on anti-counterfeiting until the outcome of the working group is accepted by member states.
With the World Health Organization director general’s term of office ending next year, WHO members today set up a drafting group to try to reconcile divergent views on the process leading to the election. Some countries are in favour of a principle of geographical rotation - citing over 60 years of no representation from their regions, while some other countries claimed rotation could override more important selection criteria such as expertise and experience, and could endanger the organisation’s future.
A seemingly overworked and impoverished World Health Organization opened its Executive Board session today with calls for reform amid deep concerns about its financial future. Meanwhile, dissension arose over an industry representative named by the WHO secretariat to a new research and development funding working group, sparking the WHO director general to cast doubt on the role of industry in such groups.
The Digital Agenda's hoped-for role as a key growth driver for Europe’s flagging economy has pushed intellectual property issues into a high-priority spot on the EU’s policy agenda for 2011. In an effort to boost job creation and innovation, the European Commission is looking to improve online content licensing, access and protection. And despite continuing opposition from several countries, the long-awaited European patent is finally moving forward. Debate is also heating up on new ways to encourage biomedical innovation, and on a proposed EU-India free trade pact.
In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how to recognise the true value of a firm’s intellectual property. Companies are realising that simply accumulating patents does not necessarily increase their firms’ value, but it is how those patents are used that can attract capital. And drug companies facing massive numbers of upcoming patent expiries, a deflated economy and other market pressures, are looking to diversify their portfolios to stay in the black.
A top Swiss company executive on pandemic influenza and HIV/AIDS research took the reins of the Geneva-based Medicines for Malaria Venture this week, just weeks after MMV was given international organisation status by the Swiss government.
A decision by the Indian Patent Office to reject a patent on an AIDS drug last week has drawn acclaim from civil society and Indian generic pharmaceutical industries. The decision was not based on a controversial article of Indian law aimed at preventing patent extensions but rather on the grounds of non-inventiveness. Abbott Laboratories, meanwhile, presented Intellectual Property Watch with justification for its Indian patent request.
At Intellectual Property Watch, a list of the top 25 posts of 2010 reveals your - our readers’ - top interests and tells the tale of the past year. It also is a reminder that quality reporting needs support. Please subscribe to IP-Watch via our website, or contact the director at wnew@ip-watch.ch.